Insmed Incorporated (INSM)
| Market Cap | 44.31B |
| Revenue (ttm) | 447.02M |
| Net Income (ttm) | -1.18B |
| Shares Out | 213.27M |
| EPS (ttm) | -6.22 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,052,640 |
| Open | 205.56 |
| Previous Close | 204.51 |
| Day's Range | 204.00 - 207.99 |
| 52-Week Range | 60.40 - 209.77 |
| Beta | 1.02 |
| Analysts | Strong Buy |
| Price Target | 173.35 (-16.57%) |
| Earnings Date | Oct 30, 2025 |
About INSM
Insmed Incorporated develops and commercializes therapies for patients with serious and rare diseases in the United States, Europe, Japan, and internationally. The company offers ARIKAYCE for the treatment of refractory nontuberculous mycobacterial lung infections, as well as is in phase 3 clinical trial for the treatment of mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients. It also devlops brensocatib, an oral reversible inhibitor of dipeptidyl peptidase 1(DPP1) that is in phase 3 c... [Read more]
Financial Performance
In 2024, Insmed's revenue was $363.71 million, an increase of 19.17% compared to the previous year's $305.21 million. Losses were -$913.77 million, 21.9% more than in 2023.
Financial StatementsAnalyst Summary
According to 19 analysts, the average rating for INSM stock is "Strong Buy." The 12-month stock price target is $173.35, which is a decrease of -16.57% from the latest price.
News
European Commission Approves BRINSUPRI™ (brensocatib) as the First and Only Treatment Approved for Non-Cystic Fibrosis Bronchiectasis in the European Union
— Non-Cystic Fibrosis Bronchiectasis (NCFB) Is a Serious, Progressive Lung Disease That Can Lead to Permanent Lung Damage — — BRINSUPRI Is a First-in-Disease, First-in-Class DPP1 Inhibitor Targeting N...
Insmed Incorporated (INSM) Presents at Jefferies London Healthcare Conference 2025 Transcript
Insmed Incorporated ( INSM) Jefferies London Healthcare Conference 2025 November 18, 2025 3:30 AM EST Company Participants William Lewis - President, CEO & Chairman Conference Call Participants Yuxi ...
Insmed Strengthens Communities Worldwide During Fourth Annual Global Day of Good
More than 1,200 employees across the U.S., Europe, and Japan unite to support multiple organizations during annual company-wide day of service BRIDGEWATER, N.J. , Nov. 13, 2025 /PRNewswire/ -- Insmed ...
Artisan Global Opportunities Fund Q3 2025 Portfolio Update
During the quarter, we initiated new positions in Spotify, L3Harris Technologies and Insmed. We also added to 3i Group, West Pharmaceutical and Amazon during the quarter. We ended our investment campa...
American Century Focused Dynamic Growth Fund Q3 2025 Performance Contributors And Detractors
Google's parent company received a relatively benign antitrust ruling that would not force Alphabet to sell its Chrome browser or Android operating system. Alnylam's shares benefited from a positive p...
Insmed To Present at November and December 2025 Investor Conferences
BRIDGEWATER, N.J. , Nov. 5, 2025 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform...
Latest read on rare disease gene therapy from Insmed CEO Will Lewis
Will Lewis, Insmed CEO, joins 'Fast Money' to talk Insmed's rare gene therapy development, demand, and quarterly results.
Insmed Incorporated (INSM) Q3 2025 Earnings Call Transcript
Insmed Incorporated ( INSM) Q3 2025 Earnings Call October 30, 2025 8:00 AM EDT Company Participants Bryan Dunn - Vice President of Investor Relations William Lewis - President, CEO & Chairman Roger A...
Insmed Reports Third-Quarter 2025 Financial Results and Provides Business Update
—BRINSUPRI ™ (brensocatib) Approved by FDA as First and Only Treatment for Non-Cystic Fibrosis Bronchiectasis; Positive CHMP Opinion Adopted in the European Union and Application Accepted in Japan— —...
Baron Health Care Fund Q3 2025 Top Contributors And Detractors
Argenx SE is a biotechnology company best known for developing Vyvgart, the leading FcRn inhibitor for the treatment of autoimmune conditions. RadNet, Inc. is the largest operator of outpatient diagno...
Insmed Ranks No. 1 on Science's 2025 Top Biopharma Employers List
—Insmed Leads Science Top Employers List for Fifth Year in a Row— BRIDGEWATER, N.J. , Oct. 23, 2025 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company ...
CHMP Recommends EU Approval of BRINSUPRI™ (brensocatib) for the Treatment of Non-Cystic Fibrosis Bronchiectasis
— If Approved, BRINSUPRI Would Be the First and Only Treatment in the European Union for Non-Cystic Fibrosis Bronchiectasis (NCFB) and the First-in-Class DPPI Inhibitor Targeting Neutrophilic Inflamma...
Insmed to Present Multiple Analyses from Phase 3 ASPEN Study at the American College of Chest Physicians Annual Meeting 2025
—Data on Structural Lung Changes from a High-Resolution CT Substudy to be Presented as Late-Breaker— —Additional Analyses Will Highlight Efficacy, Symptom Reduction, and Biomarker Suppression in Patie...
Insmed to Host Third-Quarter 2025 Financial Results Conference Call on Thursday, October 30, 2025
BRIDGEWATER, N.J. , Oct. 15, 2025 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transfor...
Insmed: De-Risked Respiratory Growth, Premium Multiple, And Real M&A Optionality
Insmed remains a compelling biotech trade after Brinsupri's FDA approval for NCFB, with strong de-risking and significant market potential. Brinsupri's aggressive pricing and broad label could drive p...
Insmed to Present Multiple Abstracts at the European Respiratory Society Congress 2025
—Data from Phase 2b Study of Treprostinil Palmitil Inhalation Powder in Patients with Pulmonary Arterial Hypertension to be Presented at Late-Breaking ALERT Session — —New Analysis from Phase 3 ASPEN...
Insmed Incorporated (INSM) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript
Insmed Incorporated (NASDAQ:INSM) Morgan Stanley 23rd Annual Global Healthcare Conference September 9, 2025 4:50 PM EDT Company Participants William Lewis - President, CEO & Chairman Conference Call ...
Insmed Incorporated (INSM) Presents At Wells Fargo 20th Annual Healthcare Conference 2025 Transcript
Insmed Incorporated (NASDAQ:INSM) Wells Fargo 20th Annual Healthcare Conference 2025 September 5, 2025 8:00 AM EDT Company Participants Sara Bonstein - Chief Financial Officer Conference Call Partici...
Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
BRIDGEWATER, N.J. , Sept. 5, 2025 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transfor...
Insmed To Present at September Investor Conferences
BRIDGEWATER, N.J. , Aug. 21, 2025 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transfor...
Lung Disease-Focused Insmed 'Must-Own' Name For Investors
William Blair initiated coverage on Insmed Incorporated INSM, citing that the clinical and commercial execution of its drugs can significantly increase Insmed's valuation.
Josh Brown's Best Stocks in the Market: Insmed
Josh Brown, CEO of Ritholtz Wealth Management, joins CNBC's "Halftime Report" to detail his latest addition to his 'Best Stocks in the Marlet,' Insmed.
Insmed CEO on what's next for company after FDA greenlights lung disease drug
Will Lewis, Insmed CEO, joins 'Fast Money' to discuss the company's lung drug being greenlit by the FDA and what it means for for the stock.
FDA Approves Insmed's Drug As First Treatment For Type Of Chronic Lung Disease
The U.S. Food and Drug Administration (FDA) on Tuesday approved Insmed Incorporated's INSM Brinsupri (brensocatib 10 mg and 25 mg tablets). It is an oral, once-daily treatment for non-cystic fibrosis ...